

## **VIVALIS ANNOUNCES A NEW EB66® RESEARCH AGREEMENT FOR THE ASSESSMENT OF MANUFACTURABILITY OF TWO HUMAN VACCINES**

**Nantes & Lyon (France) – November 13<sup>th</sup>, 2012** – VIVALIS (NYSE Euronext: VLS) announced today that it has entered into a new EB66® cell line research agreement for the evaluation of two human anti-cancer vaccine candidates in the EB66® cell line.

Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of VIVALIS jointly stated, “A successful evaluation of these vaccines, one of them currently in clinical trials, would result in a new client making the switch from egg (CEF) based production into the EB66® platform technology, which continues to be adopted by more and more companies since EB66® cells’ introduction in 2007. With ongoing human clinical trials up to Phase III and one product approved for animal health, 2012 has been an incredibly successful year for developers using EB66® cells. With 11 licenses and/or research agreements signed in 2012, we are inspired to keep this momentum going in both our existing and new markets and remain confident in our partners’ success.”

Terms of the agreement were not disclosed but do include fees for services performed by Vivalis.

\*\*\*\*\*

### **Next Financial Press Release**

**January 15<sup>th</sup>, 2013, after NYSE Euronext market closing:  
2013 Financial calendar**

### **About VIVALIS (www.vivalis.com)**

Vivalis (NYSE-Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the biotechnology and pharmaceutical industry for the manufacture of vaccines and recombinant proteins, and develops monoclonal antibodies for the prevention and treatment of diseases with unmet medical needs. Vivalis’ expertise and intellectual property are leveraged in two main areas:

#### **1. EB66® Cell Line**

Vivalis offers research and commercial licenses for its EB66® cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLPs and recombinant proteins, including monoclonal antibodies. Clinical trials of EB66® produced vaccines are currently on-going in the USA and Japan and in 2012 a vaccine produced in EB66® cells received market approval in Japan for use in animal health. Through these programs, Vivalis receives an upfront payment, clinical stage milestone payments along with royalties on licensees’ net sales.

## 2. VIVA|Screen™ Human Antibody Discovery Platform

Customized solutions for the discovery, development and production of rare, fully human monoclonal antibodies are offered by Vivalis. Through these programs, Vivalis receives payments associated with the funding of discovery research, an upfront payment, clinical stage milestone payments along with royalties on net sales of licensed antibodies that are commercially developed from the use of the platform.

Based in Nantes and Lyon (France) and in Toyama (Japan), Vivalis was founded in 1999 by the Group Grimaud (approx. 1,700 employees), one of the worldwide leaders in animal genetic selection. Vivalis has established more than 30 partnerships and licenses with world leaders in biopharmaceutical industry, including Sanofi Pasteur, GlaxoSmithKline Biologicals, Transgene, Pfizer Animal Health, Kaketsuken, Kitasato Daiichi Sankyo Vaccine, Merial, Merck Animal Health and SAFC Biosciences. Vivalis is a member of the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bio-clusters and a member of the Japanese HOKURIKU INNOVATION CLUSTER FOR HEALTH SCIENCE based in Toyama.

VIVALIS

Listed on Euronext Paris – Compartment C of NYSE Euronext

Reuters: VLS.PA – Bloomberg: VLS FP

Included in NYSE Euronext's SBF 250, CAC Small 90 and Next Biotech indexes



*This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantee can be given to any of the events anticipated by the forward-looking statements contained in this document, which are subject to inherent risks, including risk factors described in the company's Document de Référence, changes in economic conditions, the financial markets or the markets in which the company operates.*

### **Contacts**

#### **VIVALIS**

Franck Grimaud, CEO

Email: [investors@vivalis.com](mailto:investors@vivalis.com)

#### **NewCap**

Financial communications agency

Axelle Vuillermet / Pierre Laurent

Tél.: +33 (0) 1 44 71 94 93

Email : [vivalis@newcap.fr](mailto:vivalis@newcap.fr)